Invest Radiol. 1988 Aug;23(8):574-8. |
|
Radiolabeled fibronectin
for the scintigraphic detection of pulmonary emboli
in dogs.
Zoghbi SS, Sostman HD, Duberg
AC, Lwebuga-Mukasa J, Carbo
PL, Gottschalk A.
Department of Diagnostic Radiology, Yale University School of Medicine, New
Haven, Connecticut 06510.
Plasma fibronectin, a glycoprotein that is a component
of blood thrombi, was evaluated for the in vivo scintigraphic
detection of pulmonary emboli in dogs. Fibronectin
(canine or human) was labeled with either 131I or with 111In
and diethylenetriaminepenta-acetic acid (DTPA) as the bifunctional chelating
agent using a modification of the mixed anhydride method. The radiolabeled proteins were administered intravenously 20 to
30 minutes after the embolization of a 99mTc-labeled thrombus. The uptake of radioactivity by the
embolus was monitored scintigraphically up to 24
hours. At the end of each experiment, the animal was killed and in vitro tissue
counting of radioactivity was performed. Comparative study of the 131I- and
111In-labeled agent is presented with particular reference
to their pharmacokinetics. The in vivo uptake of radioactivity by the emboli
was limited, indicating that radiolabeled fibronectin is not a good scintigraphic
agent for the detection of pulmonary emboli.
PMID: 3417434 [PubMed
- indexed for MEDLINE]